相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Mary Luz Uribe et al.
CANCERS (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung
Ng Kwok Sing et al.
EUROPEAN JOURNAL OF RADIOLOGY (2020)
Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments
W. -Q. Li et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Chest imaging using signs, symbols, and naturalistic images: a practical guide for radiologists and non-radiologists
Alessandra Chiarenza et al.
INSIGHTS INTO IMAGING (2019)
Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations
Yusuke Okuma et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study
Fred Hsu et al.
ACTA ONCOLOGICA (2017)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2017)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
Yijiu Ren et al.
ONCOTARGET (2016)
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib
Kuan-Li Wu et al.
LUNG CANCER (2015)
Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis
Hee Joung Kim et al.
THORACIC CANCER (2015)
Specific organ metastases and survival in metastatic non-small-cell lung cancer
Tomohiro Tamura et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Yaxiong Zhang et al.
PLOS ONE (2014)
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
Shang-Gin Wu et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Association of Diffuse, Random Pulmonary Metastases, Including Miliary Metastases, With Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma
Yosuke Togashi et al.
CANCER (2011)
分享论文
